Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV |
| |
| Authors: | Wire Mary B Baker Katherine L Jones Lori S Shelton Mark J Lou Yu Thomas Greg J Berrey M Michelle |
| |
| Affiliation: | Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, 5 Moore Dr., 17.2231.2B, Research Triangle Park, NC 27709, USA. Mary.B.Wire@gsk.com |
| |
| Abstract: | ![]()
To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
